Application of Antiosteoporosis Therapy in Osteolysis

NCT05617846 | Not Yet Recruiting DMC

• 1 other identifier: ZZUSC-19
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Conditions

Limb; Fusion; Complication

Outcome Measures

Primary Outcomes (2)

• Complications

  The incidence of complications after anti-osteoporosis treatment was collected and the severity of complications was evaluated according to CTCAE5.0.

  Collected from the beginning of treatment to 24 months after treatment.

• Limb function

  Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.

  Collected from the beginning of treatment to 24 months after treatment.

Study Arms (2)

Intervention group

Patients who received antiosteoporosis therapy after bone tumor resection

Other: Anti-osteoporosis therapy

Control group

Patients who underwent bone tumor resection without antiosteoporosis therapy

Interventions

Anti-osteoporosis therapy OTHER

Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.

Intervention group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients receiving antiosteoporosis therapy for osteolysis after surgery for bone tumors in the extremities

You may qualify if:

• No age restriction, male or female.
• A subtype of bone tumor (including benign, malignant, and metastatic cancer) was confirmed in the pathology department of the research institution.
• Received excision of bone tumor in research institution.

You may not qualify if:

• Not applicable.

Sponsors & Collaborators

• Henan Cancer Hospital: lead

Study Sites (1)

Department of Bone and Soft Tissue ,Henan Cancer Hospital

Zhengzhou, Henan, China

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: associate chief physician

Study Record Dates

• First Submitted: October 31, 2022
• First Posted: November 16, 2022
• Study Start: December 28, 2024
• Primary Completion (Estimated): November 30, 2032
• Study Completion (Estimated): November 30, 2032
• Last Updated: January 18, 2024

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)